Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Lumosa Therapeutics Co., Ltd.

Clinicaltrial registered22 Oct 2026

Lumosa Therapeutics Co., Ltd.

22 Oct 2026: Trial registered · A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
22 Oct 2026
Title
A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant
Conditions
Acute Ischemic Stroke
Phase
Phase 2
Study Type
Interventional
Status
Recruiting
Countries
Taiwan
Country
Taiwan
Reference
NCT07890298
Location
Taiwan
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Lumosa Therapeutics Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Taiwan

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.